Angiotensin II Receptor Signaling Domains

血管紧张素 II 受体信号传导域

基本信息

  • 批准号:
    6603390
  • 负责人:
  • 金额:
    $ 34.2万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1998
  • 资助国家:
    美国
  • 起止时间:
    1998-08-18 至 2005-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: (Verbatim from the application): The renin-angiotensin system is important in normal physiology and the diseases hypertension and atherosclerosis. Angiotensin II (Ang II), interacts with, among others, the Ang II type 1A receptor (AT, AR) of vascular smooth muscle cells (VSMCs), leading to activation of several phospholipases (PL). The second or tonic phase of signaling requires endocytosis or sequestration of the AT1 4R to an undefined discrete signaling domain, a major focus of this proposal. Additionally, Ang II increases intracellular calcium, and activates protein kinase C, Src family kinases and Jak kinases, as well as mitogen activated protein kinases that mediate VSMC hypertrophy and growth. Importantly, Mg II induces robust generation of reactive oxygen species (ROS) that are major modifiers of signal generation. Calcium-dependent transactivation of the epidermal growth factor receptor (EGF R) serves as a "scaffold" for the assembly of a signaling complex including cSrc, Pyk2, and downstream adaptors (Shc, Grb2, Sos), leading to ERK1/2 and protein kinase B/Akt activation. Little is known of the spatial-temporal organization of AT,A R signaling in the VSMC membrane and how specificity is achieved. Evidence suggests that receptors and associated signaling molecules are not randomly distributed but are localized in specialized domains. Functionally distinct microdomains with characteristic lipid composition, "lipid rafts," have been identified in plasma membranes. "Rafts" localize signaling molecules including receptors, G-protein subunits, adaptor molecules, and a host of signal generating proteins. They serve as scaffolds to facilitate interactions among pathways and signaling proteins. Caveolae are cell membrane invaginations that contain the major structural protein caveolin and are specialized forms of rafts. We have shown that Ang II stimulation of VSMCs causes movement of the AT, A R into caveolae-enriched membrane fractions. Its original, basal location is undefined. Another major signaling domain is the focal adhesion or complex, which contains integrin receptors and many associated signaling molecules as well as caveolin. The EGF R has been associated with both caveolae and focal adhesions. Our preliminary data indicate that the Mg Il-induced transmodulation of the EGF-R and certain downstream pathways are dependent upon ROS and suggest involvement of both caveolin and focal adhesion associated molecules. We hypothesize that the full repertoire of Ang 11-induced signals in VSMC is dependent upon several major "scaffolds" and discrete signaling domains. To gain insight into these issues we propose three Specific Aims involving: 1) the basal location and mechanisms by which AT1ARS move to caveolae-enriched fractions; 2) determination of the functional consequences of this movement or sequestration; and 3) determination of the role of ROS in affecting the related signaling pathways. Insights gained in understanding of the mechanisms of Ang II signaling will lead to increased understanding of the pathogenesis and potential treatment of hypertension and atherosclerosis.
描述:(原文来自申请书):肾素-血管紧张素系统是

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert WAYNE ALEXANDER其他文献

Robert WAYNE ALEXANDER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert WAYNE ALEXANDER', 18)}}的其他基金

ANGIOTENSIN II RECEPTOR SIGNALING DOMAINS
血管紧张素 II 受体信号传导域
  • 批准号:
    2678111
  • 财政年份:
    1998
  • 资助金额:
    $ 34.2万
  • 项目类别:
ANGIOTENSIN II RECEPTOR SIGNALING DOMAINS
血管紧张素 II 受体信号传导域
  • 批准号:
    6184982
  • 财政年份:
    1998
  • 资助金额:
    $ 34.2万
  • 项目类别:
ANGIOTENSIN II RECEPTOR SIGNALING DOMAINS
血管紧张素 II 受体信号传导域
  • 批准号:
    6044036
  • 财政年份:
    1998
  • 资助金额:
    $ 34.2万
  • 项目类别:
Angiotensin II Receptor Signaling Domains
血管紧张素 II 受体信号传导域
  • 批准号:
    7197819
  • 财政年份:
    1998
  • 资助金额:
    $ 34.2万
  • 项目类别:
Angiotensin II Receptor Signaling Domains
血管紧张素 II 受体信号传导域
  • 批准号:
    7344741
  • 财政年份:
    1998
  • 资助金额:
    $ 34.2万
  • 项目类别:
Angiotensin II Receptor Signaling Domains
血管紧张素 II 受体信号传导域
  • 批准号:
    7536370
  • 财政年份:
    1998
  • 资助金额:
    $ 34.2万
  • 项目类别:
Angiotensin II Receptor Signaling Domains
血管紧张素 II 受体信号传导域
  • 批准号:
    6762437
  • 财政年份:
    1998
  • 资助金额:
    $ 34.2万
  • 项目类别:
Angiotensin II Receptor Signaling Domains
血管紧张素 II 受体信号传导域
  • 批准号:
    6334315
  • 财政年份:
    1998
  • 资助金额:
    $ 34.2万
  • 项目类别:
Angiotensin II Receptor Signaling Domains
血管紧张素 II 受体信号传导域
  • 批准号:
    6527169
  • 财政年份:
    1998
  • 资助金额:
    $ 34.2万
  • 项目类别:
Angiotensin II Receptor Signaling Domains
血管紧张素 II 受体信号传导域
  • 批准号:
    7738504
  • 财政年份:
    1998
  • 资助金额:
    $ 34.2万
  • 项目类别:

相似海外基金

Exploratory Efficacy-Evaluation Study of Angiotensin Receptor-Neprilysin Inhibitor in patients with dialysis
血管紧张素受体脑啡肽酶抑制剂在透析患者中​​的探索性疗效评价研究
  • 批准号:
    21K16191
  • 财政年份:
    2021
  • 资助金额:
    $ 34.2万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Personalizing Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Therapy in Chronic Kidney Disease
慢性肾脏病的个体化血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂治疗
  • 批准号:
    10313873
  • 财政年份:
    2021
  • 资助金额:
    $ 34.2万
  • 项目类别:
Strategies for Angiotensin Receptor Blocker Mediated Tissue Repair
血管紧张素受体阻滞剂介导的组织修复策略
  • 批准号:
    10469311
  • 财政年份:
    2020
  • 资助金额:
    $ 34.2万
  • 项目类别:
Impact of an Angiotensin Receptor Blocker in Aortic Stenosis - a Randomized Controlled Trial
血管紧张素受体阻滞剂对主动脉瓣狭窄的影响 - 一项随机对照试验
  • 批准号:
    433568
  • 财政年份:
    2020
  • 资助金额:
    $ 34.2万
  • 项目类别:
    Operating Grants
Strategies for Angiotensin Receptor Blocker Mediated Tissue Repair
血管紧张素受体阻滞剂介导的组织修复策略
  • 批准号:
    10649490
  • 财政年份:
    2020
  • 资助金额:
    $ 34.2万
  • 项目类别:
Strategies for Angiotensin Receptor Blocker Mediated Tissue Repair
血管紧张素受体阻滞剂介导的组织修复策略
  • 批准号:
    10210299
  • 财政年份:
    2020
  • 资助金额:
    $ 34.2万
  • 项目类别:
Strategies for Angiotensin Receptor Blocker Mediated Tissue Repair
血管紧张素受体阻滞剂介导的组织修复策略
  • 批准号:
    10065083
  • 财政年份:
    2020
  • 资助金额:
    $ 34.2万
  • 项目类别:
Mechanism of suppressive effects for atherosclerosis by Angiotensin Receptor-Neprilysin Inhibitor
血管紧张素受体脑啡肽酶抑制剂抑制动脉粥样硬化的机制
  • 批准号:
    19K17618
  • 财政年份:
    2019
  • 资助金额:
    $ 34.2万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Pathophysiological significance of angiotensin receptor-binding protein in leucocytes and immune cells
白细胞和免疫细胞中血管紧张素受体结合蛋白的病理生理意义
  • 批准号:
    19K17575
  • 财政年份:
    2019
  • 资助金额:
    $ 34.2万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Angiotensin receptor G protein signal switching in AgRP neurons in cardiometabolic control
AgRP 神经元中血管紧张素受体 G 蛋白信号转换在心脏代谢控制中的作用
  • 批准号:
    10658260
  • 财政年份:
    2017
  • 资助金额:
    $ 34.2万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了